Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes

Advances in Medical Sciences

Volumn 58, Issue 2, 2013, Pages 362-368

  Rosiak, M ^a   Postula, M ^a   Kaplon Cieslicka, A ^a   Trzepla, E ^a   Czlonkowski, A ^a   Filipiak, K J ^a   Opolski, G ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Atherosclerosis; Biguanide; Coronary artery disease; Heart failure; Insulin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; INSULIN; LOOP DIURETIC AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; UREA; URIC ACID;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DIABETIC PATIENT; FEMALE; HEART INFARCTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; THROMBOCYTE COUNT;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATHEROSCLEROSIS; BIGUANIDES; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIURETICS; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS;

EID: 84896851907     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/ams-2013-0009     Document Type: Article

References (22)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.
2. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care. 2005;28(7):1588-93.
3. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999 Sep;100(10):1132-3.
4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009 Apr;119(14):1977-2016.
5. Leibundgut G, Brunner-La Rocca HP. End-stage chronic heart failure. Swiss Med Wkly. 2007;137(7-8):107-13.
6. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55(19):2140-47.
7. Swedberg KB, Hall C, Nielsen OW, Wu AHB, Apple FS, Collinson PO, et al. New frontiers in cardiovascular management clinical experiences and state-of-the-art research on N-Terminal pro-Brain Natriuretic Peptide (NTproBNP). A report from the First International Symposium on NT-proBNP. Cardiology Scientific Update. Toronto: Shell Medical Communication Inc; May 2003. p. 1-6.
8. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338(1-2):107-15.
9. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339(13):861-7.
10. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010;106(7):1006-10.
11. Kim JY, Lee EY, Jee JH, Lee BW, Chung JH, Jeun ES, et al. N-terminal pro-brain natriuretic peptide (NTproBNP) in Type 2 diabetes with left ventricular dysfunction. Diabetes Res Clin Pract. 2007;77 Suppl 1:S238-42.
12. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J. 2008;29(18):2259-64.
13. Hamano K, Abe M, Komi R, Kobayashi S. N-terminal fragment of pro-brain natriuretic peptide (NTproBNP) for predicting silent myocardial ischaemia in type 2 diabetes mellitus independent of microalbuminuria. Diabetes Metab Res Rev. 2010;26(7):534-9.
14. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47(1):91-7.
15. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967.
16. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation. 2009;119(19):2568-77.
17. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPKeNOS- mediated signaling. Diabetes. 2008;57(3):696-705.
18. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2- dependent mechanisms. Nat Med. 2005;11(10):1096-103.
19. Russell RR 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114(4):495-503.
20. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004;10(12): 1384-9.
21. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005;67(4):705-13.
22. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301(2):H459-68.